Royal Philips has explicitly made massive, multiyear hospital contracts part of its strategy as it works to define its leadership in HealthTech, the core of its corporate vision that's tied to its healthcare and consumer products. Now it's weighed in with a massive commitment on that front, a CA$300 million ($225 million) deal to provide an existing as well as a new hospital in Ontario with medical technology procurement, management and maintenance over the next 18 years.
Roche has inked a collaboration deal with Madison, WI-based Cellular Dynamics for a supply of induced pluripotent stem cell-derived iCell products that can be used to ID new drug candidates.
IBM is teaming up with Boston Children's Hospital to use its Watson system for rare pediatric disease diagnosis and treatment, deepening its dive into healthcare as it signs on key biopharma partners to Watson and gets the ball rolling at its new global cloud computing hub in Cambridge.
South Korea's Hanmi Pharmaceutical has licensed long-acting GLP/GCG analog diabetes and obesity candidate HM12525A to Janssen Pharmaceuticals, showcasing a deal making spree this year with major drug firms that includes two blockbusters this month alone.
Alphabet's Life Sciences group is broadening its med tech cachet through a new research deal with the American Heart Association (AHA), teaming up with the organization to come up with new tools and resources to address heart disease.
Singapore-based ASLAN Pharmaceuticals has notched a first in its efforts to develop immunotherapies and targeted agents for Asia-prevalent tumor types under a refined cost model, roping in South Korea's Hyundai Pharmaceutical in a development and license deal of ASLAN001 for the treatment of a form of bile duct cancer, cholangiocarcinoma.
South Korea-based Hanmi Pharmaceutical has signed a deal with French pharma giant Sanofi to license its GLP-1 diabetes treatments as Sanofi attempts to revive its diabetes division, according to a report by Reuters.
Sanofi, stockpiling diabetes assets with eyes on Novo Nordisk and Eli Lilly, inked a deal worth up to $1.7 billion to bring in a late-stage treatment for the disease, partnering up with Lexicon Pharmaceuticals.
Sanofi signed a deal worth up to $4.2 billion to get its hands on a trio of diabetes treatments from South Korean drugmaker Hanmi Pharmaceutical, filling out its pipeline as it contends with rivals Novo Nordisk and Eli Lilly.
CRO Accelovance is pairing up with a nonprofit clinical research outfit to bring its services to the developing world.